HC Wainwright Expects Higher Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Stock analysts at HC Wainwright raised their FY2024 EPS estimates for shares of Sensus Healthcare in a report released on Monday, November 18th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.42 per share for the year, up from their prior forecast of $0.36. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.11 EPS, Q1 2025 earnings at $0.14 EPS, Q2 2025 earnings at $0.10 EPS and FY2025 earnings at $0.52 EPS.

Separately, Maxim Group upped their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $8.37 on Tuesday. Sensus Healthcare has a fifty-two week low of $2.02 and a fifty-two week high of $8.69. The firm has a 50-day simple moving average of $6.42 and a 200-day simple moving average of $6.00. The company has a market capitalization of $137.10 million, a price-to-earnings ratio of 14.75 and a beta of 1.04.

Institutional Trading of Sensus Healthcare

Hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after purchasing an additional 93,511 shares in the last quarter. Chapin Davis Inc. purchased a new position in shares of Sensus Healthcare during the 2nd quarter worth approximately $53,000. Renaissance Technologies LLC lifted its holdings in shares of Sensus Healthcare by 34.4% in the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after buying an additional 100,294 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Sensus Healthcare in the second quarter valued at approximately $156,000. Finally, Sachetta LLC grew its holdings in Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after acquiring an additional 13,544 shares during the period. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.